Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

After hours: December 23 at 6:42:47 PM EST Loading Chart for BLRX ...

The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...

However, treating patients with bendamustine/rituximab plus acalabrutinib might be preferred to either option with cytarabine. Although the results showed that the bendamustine/rituximab plus ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Moleculin Biotech (MBRX) announced the online publication of its abstract titled, “Annamycin, a non-cardiotoxic anthracycline, demonstrates ...

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

The ocean's biodiversity is a key source of marine-derived compounds, fueling pharmaceutical innovations and drug discovery ...